Your browser doesn't support javascript.
loading
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Hu, Shanlian; Tang, Zhiliu; Harrison, James P; Hertel, Nadine; Penrod, John R; May, Jessica R; Juarez-Garcia, Ariadna; Holdgate, Orban.
Afiliação
  • Hu S; School of Public Health, Fudan University, Dong'an Rd, Xuhui Qu, Shanghai, 200333, China.
  • Tang Z; Sino-American Shanghai Squibb Pharmaceuticals Ltd, 1315 Jianchuan Rd, Minhang Qu, Shanghai, 201401, China. justin_julie@sina.com.
  • Harrison JP; GlaxoSmithKline China, 6/F The Headquarters Building, 168 Tibet Rd(M), Shanghai, 200001, China. justin_julie@sina.com.
  • Hertel N; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, USA.
  • Penrod JR; Bristol Myers Squibb, Sanderson Rd, Uxbridge, UB8 1DH, UK.
  • May JR; Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, USA.
  • Juarez-Garcia A; Bristol Myers Squibb, Sanderson Rd, Uxbridge, UB8 1DH, UK.
  • Holdgate O; Bristol Myers Squibb, Sanderson Rd, Uxbridge, UB8 1DH, UK.
Pharmacoecon Open ; 7(2): 273-284, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36897427
OBJECTIVE: To evaluate the economic value of nivolumab versus docetaxel for advanced non-small cell lung cancer (aNSCLC) treatment after platinum-based chemotherapy in adults without epidermal growth factor receptor/anaplastic lymphoma kinase aberrations in China. METHODS: Partitioned survival models evaluated lifetime costs and benefits of nivolumab versus docetaxel by squamous and non-squamous histologies from a Chinese healthcare payer perspective. Progression-free disease, progressed disease, and death health states were considered over a 20-year time horizon. Clinical data were derived from the CheckMate pivotal Phase III trials (ClinicalTrials.gov identifiers: NCT01642004, NCT01673867, NCT02613507); patient-level survival data were extrapolated using parametric functions. China-specific health state utilities, healthcare resource utilisation, and unit costs were applied. Sensitivity analyses explored uncertainty. RESULTS: Nivolumab resulted in extended survival (1.489 and 1.228 life-years [1.226 and 0.995 discounted]) and quality-adjusted survival benefits (1.034 and 0.833 quality-adjusted life-years) at additional costs of ¥214,353 (US$31,829) and ¥158,993 (US$23,608) versus docetaxel in squamous and non-squamous aNSCLC, respectively. Nivolumab was associated with higher acquisition costs, lower subsequent treatment costs, and lower adverse event management costs than docetaxel in both histologies. Drug acquisition costs, discount rate for outcomes, and average body weight were key model drivers. Stochastic results aligned with the deterministic results. CONCLUSIONS: Nivolumab yielded survival and quality-adjusted survival benefits at incremental cost versus docetaxel in aNSCLC. As a traditional healthcare payer perspective was applied, the true economic benefit of nivolumab may be underestimated as not all treatment benefits and costs of relevance to society were considered.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Pharmacoecon Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Pharmacoecon Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China